These results suggest that HMGB2 knockdown, in combination with Palbociclib, effectively reduces cell proliferation in a variety of cancer models, underscoring the therapeutic potential of targeting HMGB2 in conjunction with cell cycle inhibitors. Here, HMGB2 is linked to cancer.